Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach

European Journal of Cancer

Volumn 53, Issue , 2016, Pages 163-170

  Nishino, Mizuki ^a   Brais, Lauren K ^a,b   Brooks, Nichole V ^a,b   Hatabu, Hiroto ^a   Kulke, Matthew H ^a,b   Ramaiya, Nikhil H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Computed tomography; Drug toxicity; mTOR inhibitor; Neuroendocrine tumours; Pneumonitis

Indexed keywords

EVEROLIMUS; OCTREOTIDE; PASIREOTIDE; PREDNISONE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLERGIC PNEUMONITIS; ARTICLE; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER PATIENT; COUGHING; DRUG INDUCED DISEASE; DRUG RELATED PNEUMONITIS; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HYPOXIA; INCIDENCE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROENDOCRINE TUMOR; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SORE THROAT; THORAX RADIOGRAPHY; TREATMENT DURATION; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; INTESTINAL NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; EVEROLIMUS; FEMALE; HUMANS; INTESTINAL NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PNEUMONIA; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84953312862     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.10.015     Document Type: Article

References (26)

1. J.J. Erasmus, H.P. McAdams, and S.E. Rossi High-resolution CT of drug-induced lung disease Radiol Clin North Am 40 2002 61 72
2. M. Nishino, E.N. Boswell, H. Hatabu, I.M. Ghobrial, and N.H. Ramaiya Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstrom macroglobulinemia as a Paradigm Oncologist 20 2015 1077 1083
3. M. Nishino, L.M. Sholl, F.S. Hodi, H. Hatabu, and N.H. Ramaiya Anti-PD-1-related pneumonitis during cancer immunotherapy N Engl J Med 373 2015 288 290
4. S.H. Tirumani, N.H. Ramaiya, A. Keraliya, N.D. Bailey, P.A. Ott, F.S. Hodi, and et al. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab Cancer Immunol Res 3 10 2015 Oct 1185 1192
5. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 Am J Respir Crit Care Med 165 2002 277 304
6. W.D. Travis, U. Costabel, D.M. Hansell, T.E. King Jr., D.A. Lynch, A.G. Nicholson, and et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 188 2013 733 748
7. I.M. Ghobrial, M. Gertz, B. Laplant, J. Camoriano, S. Hayman, M. Lacy, and et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia J Clin Oncol 28 2010 1408 1414
8. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, and et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
9. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, and et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
10. K. Bouabdallah, V. Ribrag, L. Terriou, J.C. Soria, and R. Delarue Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects Curr Opin Oncol 25 Suppl. 2 2013 S1 S12
11. B.J. Atkinson, D.H. Cauley, C. Ng, R.E. Millikan, L. Xiao, P. Corn, and et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes BJU Int 113 2014 376 382
12. D.A. Dabydeen, J.P. Jagannathan, N. Ramaiya, K. Krajewski, F.A. Schutz, D.C. Cho, and et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome Eur J Cancer 48 2012 1519 1524
13. J.P. Maroto, G. Hudes, J.P. Dutcher, T.F. Logan, C.S. White, M. Krygowski, and et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus J Clin Oncol 29 2011 1750 1756
14. J.C. Soria, F.A. Shepherd, J.Y. Douillard, J. Wolf, G. Giaccone, L. Crino, and et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors Ann Oncol 20 2009 1674 1681
15. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem, and et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
16. M.E. Pavel, J.D. Hainsworth, E. Baudin, M. Peeters, D. Hörsch, R.E. Winkler, and et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
17. Y. Nakayama, M. Ikeda, M. Kojima, K. Goto, M. Hara, H. Okuyama, and et al. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report Chemotherapy 59 2013 74 78
18. C. Sibertin-Blanc, E. Norguet, M. Duluc, G. Louis, J.F. Seitz, and L. Dahan Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report BMC Res Notes 6 2013 471
19. M. Nishino, S. Cardarella, S.E. Dahlberg, T. Araki, C. Lydon, D.M. Jackman, and et al. Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival Eur J Radiol 84 2015 998 1004
20. F. Panzuto, M. Rinzivillo, N. Fazio, F. de Braud, G. Luppi, M.C. Zatelli, and et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors Oncologist 19 2014 966 974
21. I. Duran, L.L. Siu, A.M. Oza, T.B. Chung, J. Sturgeon, C.A. Townsley, and et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 42 2006 1875 1880
22. R.R. Patel, J.H. Ryu, and R. Vassallo Cigarette smoking and diffuse lung disease Drugs 68 2008 1511 1527
23. T.O. Kim, I.J. Oh, H.W. Kang, S.Y. Chi, H.J. Ban, Y.S. Kwon, and et al. Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid J Korean Med Sci 27 2012 450 453
24. L. Guilleminault, P. Carre, and P. Diot Hypersensitivity pneumonitis associated with temozolomide Eur Respir J 34 2009 526
25. S. Dixit, L. Baker, V. Walmsley, and M. Hingorani Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review Anticancer Drugs 23 2012 1099 1106
26. L. Balzarini, C. Mancini, and M. Marvisi A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma Curr Drug Saf 9 2014 73 76